CHE — Chemed Corporation stock price, charts and financials

NYSE·Healthcare·Medical - Care Facilities·USA

Latest market price

539.72

-0.85-0.16%

Overview Short InterestFilings

CHEQT65Chemed Corporation·NYSE

Overview Short InterestFilings

539.72-0.16%

Loading chart...

Signal & projected range

Insider selling clusterHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PACS+0.70%$44.81 UHS-0.69%$167.87 ENSG-0.62%$176.13 EHC-1.75%$110.50 CON-1.83%$31.12 FMS-4.95%$24.01 LFST-2.66%$10.26 OPCH-0.04%$23.69

Snapshot

Index	-	P/E	27.09	EPS (ttm)	19.92	Insider Own	5.28%	Shs Outstand	13.27M	Perf Week	4.27%

Market Cap	7.16B	Forward P/E	19.61	EPS next Y	27.53	Insider Trans	-1.37%	Shs Float	13.03M	Perf Month	12.32%

Enterprise Value	7.42B	PEG	3.76	EPS next Q	6.48	Inst Own	-	Short Float	4.34%	Perf Quarter	26.72%

Income	275.00M	P/S	2.76	EPS this Y	28.12%	Inst Trans	-	Short Ratio	2.50	Perf Half Y	24.00%

Sales	2.60B	P/B	8.62	EPS next Y	7.85%	ROA	17.41%	Short Interest	566.00K	Perf YTD	26.14%

Book/sh	62.60	P/C	179.11	EPS next 5Y	7.20%	ROE	29.45%	52W High	551.69 -2.17%	Perf Year	29.17%

Cash/sh	3.01	P/FCF	21.83	EPS past 3/5Y	3.67% -1.11%	ROIC	19.99%	52W Low	365.22 47.78%	Perf 3Y	3.16%

Dividend Est.	2.40 (0.44%)	EV/EBITDA	17.21	Sales past 3/5Y	5.82% 3.99%	Gross Margin	30.44%	Volatility	2.97% 2.52%	Perf 5Y	12.40%

Dividend TTM	2.40 (0.44%)	EV/Sales	2.86	EPS Y/Y TTM	0.15%	Oper. Margin	13.46%	ATR (14)	13.32	Perf 10Y	276.56%

Dividend Ex-Date	May 28, 2026	Quick Ratio	0.89	Sales Y/Y TTM	6.75%	Profit Margin	10.60%	RSI (14)	74.68	Recom	2.67

Dividend Gr. 3/5Y	14.13% 10.76%	Current Ratio	0.91	EPS Q/Q	41.92%	SMA20	5.87%	Beta	0.51	Target Price	554.00

Payout	12.07%	Debt/Eq	0.16	Sales Q/Q	8.72%	SMA50	14.76%	Rel Volume	1.22	Prev Close	540.57

Employees	15,811	LT Debt/Eq	0.11	Earnings	Oct 27	SMA200	23.52%	Avg Volume	203.10K	Price	539.72

IPO Date	May 03, 1973	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.21% 1.24%	Net Debt/EBITDA	0.59	Volume	247,676	Change	-0.16%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Feb-27-26	Downgrade	RBC Capital	Outperform → Sector Perform
Jan-22-26	Downgrade	Jefferies	Buy → Hold	$550 → $475
Sep-02-25	Upgrade	Jefferies	Hold → Buy	$550
Nov-05-24	Reiterated	RBC Capital	Outperform	$697 → $633
May-21-24	Reiterated	RBC Capital	Outperform	$592 → $697
Apr-28-22	Reiterated	RBC Capital	Outperform	$592
Mar-11-20	Upgrade	RBC Capital	Sector Perform → Outperform
Nov-01-19	Upgrade	JMP Securities	Market Perform → Market Outperform
Jul-19-13	Downgrade	CL King	Buy → Neutral
Oct-31-12	Downgrade	CL King	Strong Buy → Buy

Latest News

Aug-03-26

Aug-03-2610:51AM

Why Chemed (CHE) is a Top Momentum Stock for the Long-Termzacks.com

Aug-01-26

Aug-01-2610:41PM

Altria Among 7 Dividend Kings To Announce Annual Dividend Increases In AugustSeekingAlpha

Jul-29-26

Jul-29-2604:04PM

Chemed Q2 Earnings Call Highlightsmarketbeat.com

03:53PM

Chemed Corporation (CHE) Q2 2026 Earnings Call Transcriptseekingalpha.com

Jul-28-26

Jul-28-2609:04PM

Chemed (NYSE:CHE) Exceeds Q2 CY2026 ExpectationsYahoo

07:01PM

Chemed (CHE) Tops Q2 Earnings and Revenue Estimateszacks.com

04:15PM

Chemed Reports Second-Quarter 2026 Resultsglobenewswire.com

03:25AM

Arrowstreet Capital Limited Partnership Has $57.59 Million Holdings in Chemed Corporation $CHEdefenseworld.net

Jul-27-26

Jul-27-2604:37AM

Entropy Technologies LP Acquires 5,979 Shares of Chemed Corporation $CHEdefenseworld.net

03:56AM

Chemed Corporation $CHE Shares Sold by Gabelli Funds LLCdefenseworld.net

Jul-21-26

Jul-21-2609:02PM

3 Reasons to Sell CHE and 1 Stock to Buy InsteadYahoo

Jul-09-26

Jul-09-2606:08AM

B of A Securities Maintains Neutral on Chemed, Raises Price Target to $510Benzinga

Jul-05-26

Jul-05-2609:36AM

Dividend Growth Stock List: 8 Names Yielding Up To 8.3%forbes.com

Jul-01-26

Jul-01-2601:00PM

Chemed To Report Second Quarter 2026 Earnings July 28, Related Conference Call To Be Held On July 29Yahoo

Jun-26-26

Jun-26-2602:04PM

Should You Hold Chemed Stock in Your Portfolio Now?Yahoo

Company

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	2,595	2,530	2,431	2,264	2,135	2,139	2,080	1,939	1,783
Cost of Goods Sold Incl. D&A	1,805	1,772	1,577	1,466	1,370	1,369	1,378	1,321	1,228
Gross Profit	790	758	854	799	765	770	701	617	555
Selling, General and Administrative Excl. Other	441	417	424	395	359	367	330	306	271
Research and Development	0	0	0	0	0	0	0	0	0
Other Operating Expense	0	0	64	63	63	60	-18	54	40
Operating Income	350	338	366	341	343	343	390	257	244
Interest Expense	6	2	2	3	5	2	2	5	5
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	25	19	35	13	-9	9	9	9	1
Net Income Before Taxes	369	356	399	350	330	350	396	262	240
Income Taxes	95	91	97	78	80	82	77	42	34
Consolidated Net Income	275	265	302	273	250	269	319	220	206
Net Income From Continuing Operations	275	265	302	273	250	269	319	220	206
Net Income	275	265	302	273	250	269	319	220	206
EPS (Recurring)	19.92	18.42	20.10	18.11	16.72	17.14	20.02	13.77	12.80
EPS (Basic, Before Extraordinaries)	19.92	18.42	20.10	18.11	16.72	17.14	20.02	13.77	12.80
EPS (Diluted)	19.92	18.42	19.89	17.93	16.53	16.85	19.48	13.31	12.23
EBITDA	431	422	464	414	393	411	455	311	283
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	27.09	23.23	26.64	32.61	30.88	31.40	27.34	33.00	23.16
Price To Sales Ratio	2.70	2.37	3.27	3.87	3.59	3.96	4.10	3.62	2.54
Gross Margin	30.44	29.96	35.13	35.29	35.83	36.00	33.70	31.82	31.13
Operating Margin	13.49	13.36	15.06	15.06	16.07	16.04	18.75	13.25	13.68
Net Margin	10.60	10.47	12.42	12.06	11.71	12.58	15.34	11.35	11.55
Shares Outstanding	13	14	15	15	15	16	16	16	16
Market Capitalization	7,016	5,990	7,947	8,771	7,656	8,465	8,522	7,028	4,532
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCNAMARA KEVIN J	president and CEO	Aug 03 '26	Sale	539.51	2,000	1,079,020	70,418	Aug 04
MCNAMARA KEVIN J	president and CEO	Aug 03 '26	Option Exercise	445.35	2,001	891,145	264,158	Aug 04
MCNAMARA KEVIN J	president and CEO	Jul 31 '26	Option Exercise	445.35	2,001	891,145	92,220	Aug 04
GRACE PATRICK P	Director	Jul 31 '26	Sale	532.00	190	101,080	3,533	Aug 03
LINDELL ANDREA R	Director	Jun 09 '26	Sale	447.33	1,347	602,554	4,578	Jun 10
WALSH GEORGE J III	Director	May 29 '26	Sale	437.83	500	218,915	3,209	May 29
GRACE PATRICK P	Director	May 08 '26	Sale	425.78	60	25,547	3,337	May 08
MCNAMARA KEVIN J	president and CEO	May 01 '26	Sale	421.13	2,000	842,260	90,219	May 04
MCNAMARA KEVIN J	president and CEO	Mar 27 '26	Sale	369.37	1,500	554,055	92,219	Mar 30
MCNAMARA KEVIN J	president and CEO	Mar 12 '26	Sale	403.18	2,000	806,360	93,719	Mar 13
Witzeman Michael D	VP & Chief Financial Officer	Feb 13 '26	Option Exercise	0.00	666	0	6,073	Feb 17
MCNAMARA KEVIN J	president and CEO	Feb 13 '26	Option Exercise	0.00	4,374	0	96,911	Feb 17
Judkins Brian C	VP and Chief Legal Officer	Feb 13 '26	Option Exercise	0.00	566	0	2,538	Feb 17
Wherley Joel L	CEO - Vitas Healthcare	Feb 13 '26	Option Exercise	0.00	440	0	1,290	Feb 17
LEE SPENCER S	executive vice president	Feb 13 '26	Option Exercise	0.00	804	0	15,066	Feb 17

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.